{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:41:03Z","timestamp":1762004463361},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,7,31]]},"DOI":"10.1097\/qad.0b013e328360ea1e","type":"journal-article","created":{"date-parts":[[2013,3,12]],"date-time":"2013-03-12T12:42:56Z","timestamp":1363092176000},"page":"1941-1947","source":"Crossref","is-referenced-by-count":5,"title":["The IL28B effect on hepatitis C virus kinetics among HIV patients after the first weeks of pegylated-interferon\/ribavirin treatment varies according to hepatitis C virus-1 subtype"],"prefix":"10.1097","volume":"27","author":[{"given":"Antonio","family":"Rivero-Juarez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis F.","family":"Lopez-Cortes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Camacho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Caruz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Almudena","family":"Torres-Cornejo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loreto","family":"Martinez-Due\u00f1as","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"Ruiz-Valderas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian","family":"Torre-Cisneros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia","family":"Gutierrez-Valencia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Rivero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-11-20210130","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1001\/jama.292.23.2839","article-title":"Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.","volume":"292","author":"Carrat","year":"2004","journal-title":"JAMA"},{"key":"R3-11-20210130","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa040842","article-title":"Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.","volume":"351","author":"Torriani","year":"2004","journal-title":"N Engl J Med"},{"key":"R4-11-20210130","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1056\/NEJMoa032653","article-title":"Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.","volume":"351","author":"Chung","year":"2004","journal-title":"N Engl J Med"},{"key":"R5-11-20210130","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/00002030-200409030-00003","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIVHCV co-infected patients.","volume":"18","author":"Laguno","year":"2004","journal-title":"AIDS"},{"key":"R6-11-20210130","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"American Association for the Study of Liver DiseasesDiagnosis, management, and treatment of hepatitis C: an update.","volume":"49","author":"Ghany","year":"2009","journal-title":"Hepatology"},{"key":"R7-11-20210130","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/COH.0b013e32834bd365","article-title":"HIVhepatitis C coinfection natural history and disease progression.","volume":"6","author":"Hernandez","year":"2011","journal-title":"Curr Opin HIV AIDS"},{"key":"R11-11-20210130","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection.","volume":"364","author":"Jacobson","year":"2011","journal-title":"N Engl J Med"},{"key":"R12-11-20210130","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection.","volume":"364","author":"Poordad","year":"2011","journal-title":"N Engl J Med"},{"key":"R13-11-20210130","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.cld.2011.05.006","article-title":"The HIVHCV-coinfected patient and new treatment options.","volume":"15","author":"Vachon","year":"2011","journal-title":"Clin Liver Dis"},{"key":"R14-11-20210130","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1097\/QAD.0b013e328348a7ac","article-title":"Low-density lipoprotein receptor genotyping enhances the predictive value of IL28B genotype in HIVhepatitis C virus-coinfected patients.","volume":"25","author":"Pineda","year":"2011","journal-title":"AIDS"},{"key":"R15-11-20210130","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1086\/656235","article-title":"Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus.","volume":"51","author":"Pineda","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R16-11-20210130","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/jac\/dkr439","article-title":"Association between the IL28B genotype and hepatitis C viral kinetics in the early days of treatment with pegylated interferon plus ribavirin in HIVHCV co-infected patients with genotype 1 or 4.","volume":"67","author":"Rivero-Juarez","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"R17-11-20210130","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1002\/hep.23912","article-title":"IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C.","volume":"52","author":"Urban","year":"2010","journal-title":"Hepatology"},{"key":"R18-11-20210130","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1097\/QAD.0b013e3283528b1c","article-title":"LDLr genotype modifies the impact of IL28B on HCV viral kinetics after the first weeks of treatment with PEG-IFNRBV in HIVHCV patients.","volume":"26","author":"Rivero-Juarez","year":"2012","journal-title":"AIDS"},{"key":"R19-11-20210130","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/hep.25647","article-title":"Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response.","volume":"56","author":"Naggie","year":"2012","journal-title":"Hepatology"},{"key":"R20-11-20210130","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1002\/jmv.21583","article-title":"Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy.","volume":"81","author":"Legrand-Abravanel","year":"2009","journal-title":"J Med Virol"},{"key":"R21-11-20210130","doi-asserted-by":"crossref","first-page":"8211","DOI":"10.1128\/JVI.00487-07","article-title":"Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy.","volume":"81","author":"Donlin","year":"2007","journal-title":"J Virol"},{"key":"R22-11-20210130","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1086\/521857","article-title":"The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection.","volume":"45","author":"Vergara","year":"2007","journal-title":"Clin Infect Dis"},{"key":"R23-11-20210130","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1053\/j.gastro.2006.02.015","article-title":"Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin.","volume":"130","author":"Berg","year":"2006","journal-title":"Gastroenterology"},{"key":"R24-11-20210130","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.jhep.2010.07.037","article-title":"Pretreatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors.","volume":"54","author":"Kurosaki","year":"2011","journal-title":"J Hepatol"},{"key":"R25-11-20210130","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1159\/000252787","article-title":"HCV genetic elements determining the early response to peginterferon and ribavirin therapy.","volume":"53","author":"Enomoto","year":"2010","journal-title":"Intervirology"},{"key":"R26-11-20210130","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1056\/NEJM199601113340203","article-title":"Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection.","volume":"334","author":"Enomoto","year":"1996","journal-title":"N Engl J Med"},{"key":"R27-11-20210130","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/hep.24453","article-title":"Impact of viral amino acid substitutions and host interleukin-28b polymorphism on replication and susceptibility to interferon of hepatitis C virus.","volume":"54","author":"Hiraga","year":"2011","journal-title":"Hepatology"},{"key":"R28-11-20210130","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/1471-2334-11-124","article-title":"Core mutations, IL28B polymorphisms and response to peginterferonribavirin treatment in Swedish patients with hepatitis C virus genotype 1 infection.","volume":"11","author":"Alestig","year":"2011","journal-title":"BMC Infect Dis"},{"key":"R29-11-20210130","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1086\/652500","article-title":"Positive selection of core 70Q variant genotype 1b hepatitis C virus strains induced by pegylated interferon and ribavirin.","volume":"201","author":"Kurbanov","year":"2010","journal-title":"J Infect Dis"},{"key":"R30-11-20210130","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/hep.25794","article-title":"Introduction to the genetics and biology of interleukin-28B.","volume":"56","author":"Urban","year":"2012","journal-title":"Hepatology"},{"key":"R31-11-20210130","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1002\/hep.25826","article-title":"Comprehensive analysis for viral elements and interleukin-28B polymorphisms in response to pegylated interferon plus ribavirin therapy in hepatitis C virus 1B infection.","volume":"56","author":"Maekawa","year":"2012","journal-title":"Hepatology"},{"key":"R32-11-20210130","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1111\/j.1478-3231.2011.02571.x","article-title":"Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg interferon and ribavirin therapy.","volume":"31","author":"Hayashi","year":"2011","journal-title":"Liver Int"},{"key":"R33-11-20210130","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1136\/gut.2010.223495","article-title":"HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy.","volume":"60","author":"Hayes","year":"2011","journal-title":"Gut"}],"container-title":["AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/QAD.0b013e328360ea1e","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T05:35:30Z","timestamp":1620970530000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002030-201307310-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,31]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/qad.0b013e328360ea1e","relation":{},"ISSN":["0269-9370"],"issn-type":[{"value":"0269-9370","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7,31]]}}}